newwin
Luciann Nguyen
Settings
← Accounts
biotech

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

50
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

New trial — A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

New trialNCT07562581
50/100
Opportunity
Commercial fit6/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency3/5

New phase 2 trial NCT07562581 posted by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.: "A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC". New trial on a phase 2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 6 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT07562581
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
phase 2
mol. elig.